U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07318675) titled 'A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.' on Dec. 16, 2025.
Brief Summary: This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Study Start Date: Dec. 25, 2025
Study Type: INTERVENTIONAL
Condition:
Actinic Keratosis (AK)
Intervention:
DRUG: HW211026
Dose 1 and Dose 2
DRUG: Placebo
Dose 1 and Dose 2
Recruitment Status: RECRUITING
Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Published by...